Common Contracts
4 similar null contracts by Air Products & Chemicals Inc /De/, Bristol Myers Squibb Co, Lockheed Martin Corp, Merck & Co. Inc.
Lockheed Martin CorporationLockheed Martin Corp • May 19th, 2020 • Guided missiles & space vehicles & parts • New York
Lockheed Martin Corporation, a Maryland corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of $400,000,000 principal amount of 1.850% Notes due 2030 of the Company (the “2030 Notes”) and an aggregate of $750,000,000 principal amount of 2.800% Notes due 2050 of the Company (the “2050 Notes”) (collectively, the “Securities”).
Air Products and Chemicals, Inc. $400,000,000 3.350% Notes due 2024 Underwriting AgreementAir Products & Chemicals Inc /De/ • July 31st, 2014 • Industrial inorganic chemicals • New York
The Securities are to be issued pursuant to an indenture, dated as of January 10, 1995 (as it may be supplemented or amended from time to time, the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as successor to U.S. Bank National Association (formerly Wachovia Bank, National Association and initially First Fidelity Bank, National Association), as trustee (the “Trustee”).
MERCK & CO., INC. Form of Debt Underwriting AgreementMerck & Co. Inc. • December 18th, 2009 • Pharmaceutical preparations • New York
Merck & Co., Inc., a New Jersey corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the firms named in Schedule I hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of $ principal amount of its % Notes due (the “Securities”).
Bristol-Myers Squibb Company Underwriting AgreementBristol Myers Squibb Co • May 7th, 2008 • Pharmaceutical preparations • New York
Bristol-Myers Squibb Company, a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the principal amount of its securities identified in Schedule I hereto (the “Securities”), to be issued under an indenture (the “Indenture”) dated as of June 1, 1993, as supplemented by a supplemental indenture, to be dated as of May 1, 2008 (collectively, the “Indenture”), between the Company and The Bank of New York (as successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (successor to The Chase Manhattan Bank (National Association)))), as Trustee (the “Trustee”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall me
